OncLive TV

Shirley Michelle Shiller, DO, member of the Precision Medicine Institute’s Advisory Committee, Baylor University Medical Center, discusses the emerging technology of liquid biopsies and the clinical success associated with them.

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses developments being made to chimeric antigen receptor (CAR) T-cell therapy for patients with hematologic malignancies.

Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, discusses the unmet need for symptom control in patients with gastrointestinal cancers.

Matthew J. Ellis, MD, PhD, professor of oncology and medicine at Baylor College of Medicine, discusses developments with immunotherapy for patients with HER2-positive breast cancer.

Weiyun Z. Ai, MD, PhD, assistant clinical professor, Department of Medicine, University of California San Francisco, speaks to the relevance of mogamulizumab (Poteligeo) in treating Sezary syndrome, a rare and aggressive form of cutaneous T-cell lymphoma

Umesh Mahantshetty, MD, MBBS, radiation oncologist, Tata Memorial Hospital, Mumbai, discusses challenges with a trial (NCT00193791) conducted by Tata Memorial Hospital seeking to solidify the impact of concomitant chemoradiation with FIGO stage IIIb squamous cervical cancer.

Catherine Smith, MD, assistant professor, Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, discusses developing active therapeutic combinations for the treatment of patients with acute myeloid leukemia

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the results of a trial investigating the combination of CTLA-4 and PD-1 inhibitors for patients with multiple myeloma.

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses sequencing challenges for patients with advanced lung cancer.

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses the tolerability of ramucirumab (Cyramza) plus pembrolizumab (Keytruda) in gastric or gastroesophageal (GEJ) cancer.

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the quality of life findings for a dose-escalation study of regorafenib (Stivarga) in metastatic colorectal cancer.

David H. Ilson, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a trial from Germany comparing standard perioperative ECF/ECX chemotherapy with a regimen combining 5-FU (5-fluorouracil) with oxaliplatin and docetaxel.

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses chimeric antigen receptor (CAR) T-cell therapy in lymphoma.

Alicia Morgan, MD, Mather Hospital, discusses enrolling patients with prostate cancer onto clinical trials investigating PARP inhibitors.

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses treatment options for patients with newly diagnosed prostate cancer.

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses novel immunotherapy combinations for patients with metastatic renal cell carcinoma (RCC).

Andrea B. Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses managing immune-related toxicities from checkpoint inhibitors in patients with bladder cancer.

David Maloney, MD, PhD, professor of medicine, Division of Oncology, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the success and challenges of chimeric antigen recptor (CAR) T-cell therapy in hematologic malignancies.

Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses when to give docetaxel as a treatment option for patients with prostate cancer.

Gabriel Mannis, MD, assistant professor, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses new methods of treatment for acute myeloid leukemia.

Nina Shah, MD, associate professor, Department of Medicine, University of California, San Francisco Helen Diller Comprehensive Cancer Center, classifies two antibody-type treatments for patients with myeloma.

Jeffrey Wolf, MD, clinical professor, Department of Medicine, director, Myeloma Program, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, details the role maintenance therapy has in treating patients with myeloma.

Alexandra Taylor, MD, consultant, clinical oncology, The Royal Marsden Hospital, discusses the management of endometrial cancer.

Assuntina G. Sacco, MD, assistant professor of medicine, medical oncologist, UC San Diego Health, discusses the importance of multidisciplinary care in the treatment of patients with head and neck cancer.

Joshua Richter, MD, a hematologist/oncologist specializing in multiple myeloma at the John Theurer Cancer Center discusses symptom management in patients with multiple myeloma.

Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses how to determine patients with high-risk chronic lymphocytic leukemia (CLL).

Malcom Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses the significant results of the PROTECT study for patients with prostate cancer.

Eileen O’Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center discusses areas of research for patients with pancreatic cancer.

Paul B. Chapman, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, professor of medicine at the Weill Cornell Medical College, discusses targeted treatments for non-traditional mutations in melanoma.

Jeffrey S. Weber, MD, PhD, Laura and Isaac Perlmutter Professor of Oncology, deputy director, co-director of the Melanoma Research Program, NYU Langone’s Perlmutter Cancer Center, discusses the clinical potential and monetary hindrances of triplet and four-drug regimens for patients with melanoma.